Navigation Links
Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership
Date:2/4/2009

LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary of Schering-Plough, to develop a 'proof of concept' vaccine against the Chikungunya virus. This vaccine aims to reduce the rate of Chikungunya infections.

Viral disease epidemics have increased in incidence around the world in recent decades. One of these diseases is caused by the Chikungunya virus, which is transmitted by mosquitoes. Originally, the disease was confined to Africa, but later spread to countries in Asia. Several cases of this disease have now been confirmed in various European countries. It appears to be spread by travelers returning from affected countries. In France, there have been more than one hundred cases and in Italy a few hundred. It seems evident that the mosquitoes able of transmitting this disease are also present in Europe. Whether or not the virus will spread further throughout Europe remains to be seen.

Virologist Ab Osterhaus, one of the research supervisors, says: "Considering the increasing spread of the Chikungunya virus in Asia, and probably also in Europe in the future, it is important to develop a vaccine against this virus that can be used not only to protect people living in the endemic area, but also travelers traveling to those areas.

The groups that are going to work together in this project have extensive expertise in the field of exotic viral infectious diseases as well as significant experience with the newest technologies in the field of vaccine development."

This TI Pharma project has a budget of EUR 2.3 million and aims to achieve a 'proof of concept' vaccine by the year 2012.

Chikungunya is a serious viral illness, which is transmitted by the Asian tiger mosquito. The disease causes a sudden high fever, a rash and intense joint pain, which can result in disability, which can last several months. There is currently no vaccine or treatment available to combat this disease.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, in malignant ... Surviving Mesothelioma has just posted an article on the new study. Click here ... study on the fact the Manumycin A, a derivative of Streptomyces parvulus, is known ...
(Date:5/19/2016)... , May 19, 2016  AdvancedFlow Systems Inc. ... (AGI), based out of Maple Ridge, ... Ltd. to its existing portfolio of contract manufacturing ... AFS along with its sister companies Surround Technologies ... vertically integrated industrial group that specializes in providing ...
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific Instruments ... University of Toledo. This two-day camp will take place annually starting June 2016. ... of pharmaceutical sciences in preparation for a university academic program. , The ...
Breaking Biology Technology:
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/9/2016)... GARDENS, Fla. , March 9, 2016 /PRNewswire/ ... management authentication and enrollment solutions, today announced the ... DigitalPersona ® Altus multi-factor authentication platform. ... and InfoSec managers to step-up security where it,s ... Washington, DC . ...
Breaking Biology News(10 mins):